Preimplantation genetic screening (PGS) by array-comparative genomic hybridization (CGH) on day 5 embryos with day 6 fresh transfer in repeated implantation failure (RIF) patients: a randomised double-blinded study

BlueGnome Ltd (UK)0 个研究点目标入组 200 人开始时间: 2011年12月9日最近更新: 2017年7月3日

适应症

试验速览

暂无简介。

•1. Female patients aged 36 years old or younger undergoing an Intra-cytoplasmic sperm injection (ICSI) attempt at GENERA Clinic in Rome
•2. History of more than two failed In vitro fertilisation (IVF)/ICSI cycles; without clinical pregnancy with transfer of at least one good quality embryos per transfer
•3 .=6 metaphase II (MII) oocytes retrieved
•4. Signed consent form

•1. Azoospermic male partner
•2. Severe male factor infertility defined as ejaculate sperm of < 1million sperm/ml
•3. Hydrosalpinx
•4. Polycystic ovary syndrome (PCOS)
•5. Pre-implantation genetic diagnosis (PGD) cycles [Single Gene Disorders (SGD) or Translocations or other chromosomal abmormalities]
•6. Female patients with pathological uterine cavity
•7. Number of retrieved MII oocytes < 6
•8. Known American Society for Reproductive Medicine (ASRM) Grade III or IV endometriosis
•9. Maternal disease that is not clinically stable and known to impact the ability to become pregnant or carry a pregnancy to term (lupus, chronic liver or kidney disease, body mass index (BMI) >35, uncontrolled hypertension, anti-phospholipid antibody, thrombophilia, insulin dependent diabetes)

发起方

BlueGnome Ltd (UK)